News Sentiment

FULC sentiment intelligence

Fulcrum Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 30 Cautious news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.70 Week of 19 Jun 2026
Weighted tone 30/100

Cautious news tone

Market reaction Bad news being absorbed

Cautious headlines are being absorbed by price, which can signal underlying demand.

Primary event Market update

78/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+7.2% over one week, -43.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

Market Reaction

Bad news being absorbed

81/100 confidence

Cautious headlines are being absorbed by price, which can signal underlying demand.

Primary event Market update 78/100 classification
One-week reaction 7.2% Price confirming higher
Trend fit Trend inactive -43.7% over four weeks
Fair value -43.3% Below fair value
Caution agrees with inactive trend

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 4
Neutral 22
Negative 25

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 7
ACCESS Newswire 5
NewMediaWire 4
Investing.com 4
TradingKey 3
simplywall.st 3
PR Newswire 2

Event Lens

What the news is about

Classified themes
Market update 26
Regulatory and legal 12
Earnings 8
Deals and strategy 3
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
NewMediaWire Direct company coverage

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about its benefit-risk profile. The FDA concluded that a

Tone
Negative 8/100
Event
Market update
Published
20 Jun 2026 12:39
Source
NewMediaWire
FinancialContent Direct company coverage

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's be

Tone
Negative 9/100
Event
Market update
Published
19 Jun 2026 10:30
Source
FinancialContent
NewMediaWire Direct company coverage

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement of discontinuing its pociredir program for sickle cell disease due to heightened FDA concerns

Tone
Negative 11/100
Event
Regulatory and legal
Published
18 Jun 2026 15:12
Source
NewMediaWire
TradingKey Direct company coverage

Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates

Fulcrum Therapeutics Inc (FULC) has an earnings forecast score of 5.78, ranking 337th in the Biotechnology & Medical Research industry. Analysts have an average price target of $20.00, with a range of $5.00 to $25.00. Based on ratings from 9 analysts, the consensus is to "Hold" F

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 08:40
Source
TradingKey
NewMediaWire Direct company coverage

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's ben

Tone
Negative 10/100
Event
Regulatory and legal
Published
17 Jun 2026 18:40
Source
NewMediaWire
ACCESS Newswire Direct company coverage

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) after the company disclosed concerns from the U.S. FDA regarding a malignancy risk with its lead candidate, pociredir, leading to its discontin

Tone
Negative 28/100
Event
Regulatory and legal
Published
17 Jun 2026 11:00
Source
ACCESS Newswire
TradingKey Direct company coverage

Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the major shareholder structure and institutional holdings of Fulcrum Therapeutics Inc (FULC). It lists the top individual shareholders and classifies shareholders by type, such as hedge funds and investment advisors. The report also provides a historical ove

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 06:11
Source
TradingKey
The National Law Review Direct company coverage

FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan F

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about its benefit-risk profile and malignancy risk. Following this announcement o

Tone
Negative 14/100
Event
Market update
Published
16 Jun 2026 23:10
Source
The National Law Review
ACCESS Newswire Direct company coverage

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) securities. This investigation follows Fulcrum's disclosure that the FDA raised concerns about a potential malignancy risk with PRC2 inhibition

Tone
Negative 5/100
Event
Regulatory and legal
Published
15 Jun 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding malignancy risk associated with PRC2 inhibition. Fulcrum announced the discontinuation of

Tone
Negative 13/100
Event
Market update
Published
14 Jun 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Fulcrum Therapeutics, Inc. (FULC) on behalf of investors. This investigation follows Fulcrum's disclosure of FDA concerns about a potential malignancy risk associated with PRC2 inhibition, leading the co

Tone
Negative 9/100
Event
Regulatory and legal
Published
12 Jun 2026 16:39
Source
ACCESS Newswire
Stock Titan Direct company coverage

Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart

Fulcrum Therapeutics has implemented special retention and change-in-control protections for its remaining leadership following a major restructuring tied to discontinuing the development of pociredir for sickle cell disease. CEO Alex C. Sapir, Chief Legal Officer Curtis Oltmans,

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Tang entities report 5,451,800‑share stake in Fulcrum (FULC)

Tang Capital Management and affiliated entities have reported a combined stake of 5,451,800 shares, representing 8.2% of Fulcrum Therapeutics (FULC) common stock. This beneficial ownership involves shared voting and dispositive power among the Tang group, as detailed in a Schedul

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jun 2026 22:39
Source
Stock Titan
NewMediaWire Direct company coverage

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after FDA concerns regarding the drug's benefit-ris

Tone
Negative 9/100
Event
Market update
Published
10 Jun 2026 18:39
Source
NewMediaWire
PR Newswire Direct company coverage

Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky

Levi & Korsinsky, LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after its shares dropped by approximately 50% following a disclosure that the FDA raised safety concerns regarding PRC2 inhibition. The company subsequently discontinued its lead sickle cell disease

Tone
Negative 14/100
Event
Regulatory and legal
Published
10 Jun 2026 05:40
Source
PR Newswire
ACCESS Newswire Direct company coverage

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) after the company announced it was discontinuing the development of its lead candidate, pociredir, due to FDA concerns about a potential malignancy ri

Tone
Negative 9/100
Event
Regulatory and legal
Published
09 Jun 2026 11:00
Source
ACCESS Newswire
MSN Direct company coverage

Fulcrum plunges after discontinuing lead program

Fulcrum Therapeutics announced it is discontinuing the development of its lead program, losmapimod, for facioscapulohumeral muscular dystrophy (FSHD) after it failed to meet its primary endpoint in a Phase 3 trial. This decision led to a significant drop in its stock price and a

Tone
Negative 13/100
Event
Market update
Published
08 Jun 2026 09:39
Source
MSN
PR Newswire Direct company coverage

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Levi & Korsinsky has initiated an investigation into the officers and directors of Fulcrum Therapeutics, Inc. (FULC) following a significant stock collapse. The investigation stems from the company's discontinuation of its pociredir program due to FDA safety concerns, despite pri

Tone
Negative 26/100
Event
Regulatory and legal
Published
06 Jun 2026 07:39
Source
PR Newswire
Sahm Direct company coverage

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics stock experienced volatility on Thursday after the company discontinued its lead experimental sickle cell disease drug, pociredir, due to FDA concerns about malignancy risks. This decision followed FDA interactions highlighting risks similar to another PRC2 i

Tone
Negative 9/100
Event
Market update
Published
06 Jun 2026 03:39
Source
Sahm
Fierce Biotech Direct company coverage

Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks

Fulcrum Therapeutics has discontinued its clinical-stage program for pociredir, a sickle cell disease treatment, after the FDA raised concerns about potential malignancy risks associated with its mechanism of action. This decision follows the withdrawal of Ipsen’s similar drug, T

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 19:10
Source
Fierce Biotech
The Business Journals Direct company coverage

Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives

Fulcrum Therapeutics is laying off 85% of its workforce, notifying employees on Thursday. The Cambridge biotech has enlisted Leerink Partners to explore strategic alternatives such as a merger or acquisition. This move comes as the company navigates its future options.

Tone
Negative 9/100
Event
Deals and strategy
Published
05 Jun 2026 17:39
Source
The Business Journals
GlobeNewswire Direct company coverage

Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)

Levi & Korsinsky, LLP has announced an investigation into potential securities claims against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant 50% stock drop. This plunge occurred after Fulcrum disclosed that the FDA raised class-wide safety concerns about PRC2-t

Tone
Negative 8/100
Event
Regulatory and legal
Published
05 Jun 2026 12:59
Source
GlobeNewswire
Simply Wall Street Direct company coverage

A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review

Fulcrum Therapeutics (FULC) is undergoing a significant re-evaluation after halting its sickle cell drug pociredir due to FDA concerns, leading to a 52.5% drop in share price over seven days. While some narratives suggest the stock is undervalued at $3.22, with a fair value estim

Tone
Negative 36/100
Event
Market update
Published
05 Jun 2026 00:09
Source
Simply Wall Street
Stock Titan Direct company coverage

Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review

Fulcrum Therapeutics is undergoing a major restructuring, reducing its workforce by 85% (from 57 to 9 employees) and incurring $4.2 million in related charges, primarily due to the discontinuation of its sickle cell disease program, pociredir. The company has engaged Leerink Part

Tone
Negative 30/100
Event
Deals and strategy
Published
04 Jun 2026 20:09
Source
Stock Titan
Business Wire Direct company coverage

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Levi & Korsinsky is investigating Fulcrum Therapeutics, Inc. (FULC) for potential securities fraud after its stock plunged approximately 50% on June 1, 2026. This drop followed the company's disclosure of FDA safety concerns related to its PRC2 inhibitor drug class, leading to th

Tone
Negative 5/100
Event
Regulatory and legal
Published
04 Jun 2026 19:09
Source
Business Wire
Market source Direct company coverage

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

Fulcrum Therapeutics (FULC) has shown sharp volatility after discontinuing its lead sickle cell drug, pociredir, and undergoing a major restructuring. While analysts suggest the stock is undervalued at $3.37 with a fair value of $19 based on future growth, Simply Wall St's DCF mo

Tone
Negative 36/100
Event
Market update
Published
04 Jun 2026 06:40
Source
Market source
Morningstar Direct company coverage

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

SueWallSt is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company's stock dropped approximately 50% following an FDA disclosure regarding class-wide safety concerns for PRC2-targeting agents, which led to the discontinu

Tone
Negative 18/100
Event
Regulatory and legal
Published
03 Jun 2026 15:09
Source
Morningstar